Trials / Conditions / Respiratory Disorders

Respiratory Disorders

29 registered clinical trials studyying Respiratory Disorders — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Effects of Pulmonary Rehabilitation in Salt Chambers on Functional Efficiency, Respiratory Parameters, and Blo NCT06951633	University School of Physical Education, Krakow, Poland	N/A
Completed	Exercise Impact in Elderly With Multimorbidity: HbA1c and Blood Pressure NCT06879639	Universidade do Porto	N/A
Completed	Study to Assess the Immunogenicity and Safety of GSK's Investigational Vaccine (GSK3277511A) When Given to Hea NCT03894969	GlaxoSmithKline	Phase 2
Completed	A Study to Test if a Third Dose of the Vaccine is Safe in Current and Former Smokers Aged 40 to 80 Years Old a NCT03443427	GlaxoSmithKline	Phase 2
Completed	A Study to Test if the Vaccine is Working Well in Chronic Obstructive Pulmonary Disease (COPD) Patients Aged 4 NCT03281876	GlaxoSmithKline	Phase 2
Completed	Ventilator Hyperinflation and Hemodynamics NCT03557645	Centro Universitário Augusto Motta	N/A
Completed	Occurrence of Potential Bacterial and Viral Pathogens in Stable Chronic Obstructive Pulmonary Disease and Duri NCT03151395	GlaxoSmithKline	N/A
Completed	A Long Term Follow-up Study up to 4 Years After Study Vaccination to Assess Immunogenicity and Safety of the I NCT03201211	GlaxoSmithKline	Phase 1
Completed	A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the Investigational GSK Biologicals' GSK3 NCT02547974	GlaxoSmithKline	Phase 1
Completed	Bioequivalence of GW483100 10 Milligram (mg) Tablets in Healthy Subjects Under Fasting Conditions NCT02658422	GlaxoSmithKline	Phase 1
Completed	Relative Bioavailability Study of Two Montelukast Sodium (GW483100) 5 Milligrams (mg) Chewable Tablets and One NCT02322671	GlaxoSmithKline	Phase 1
Recruiting	Use of Hyperpolarized 129Xe MR Lung Imaging in Adults for Calibration NCT02316379	Children's Hospital Medical Center, Cincinnati	Phase 1 / Phase 2
Recruiting	Use of Hyperpolarized Xenon Gas for Lung Imaging in Children and Adults NCT02272049	Children's Hospital Medical Center, Cincinnati	Phase 1 / Phase 2
Completed	A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GlaxoSmithkline (GSK) Biologicals' Invest NCT02075541	GlaxoSmithKline	Phase 2
Withdrawn	Proprioceptive Postural Control and Diaphragm Paresis NCT01505556	KU Leuven	—
Completed	A Study to Investigate the Safety Tolerability Pharmacokinetics, and Pharmacodynamics of Inhaled and Intraveno NCT01818024	GlaxoSmithKline	Phase 1
Completed	A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Non-typeable Haemophilus NCT01678677	GlaxoSmithKline	Phase 1
Completed	Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Non-typeable Haemophilus Influ NCT01657526	GlaxoSmithKline	Phase 1
Completed	A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of Inha NCT01587807	GlaxoSmithKline	Phase 1
Completed	A Study to Assess Immunity to Specific Microbial Antigens in Healthy Smokers and Non-smokers and in Subjects W NCT01516437	GlaxoSmithKline	N/A
Completed	Inspiratory Muscle Training and Low Back Pain NCT01505582	KU Leuven	N/A
Completed	Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of L NCT01443845	AstraZeneca	Phase 4
Withdrawn	Electrocardiographic Autonomic Function Measures in Mechanically Ventilated Patients NCT00844935	University of California, San Francisco	—
Completed	Infectious Pathogens in Acute Respiratory Illness in Adults and Elderly NCT01360398	GlaxoSmithKline	N/A
Completed	Safety Study of GSK1995057 Given as Single and Repeat Intravenous Doses in Healthy Subjects. NCT01476046	GlaxoSmithKline	Phase 1
Completed	Timing of Planned Caesarean Section and Morbidity of the Newborn NCT00835003	Aarhus University Hospital	N/A
Completed	Special Drug Use Investigation for ADOAIR (Fluticasone/Salmeterol) NCT01395862	GlaxoSmithKline	—
Completed	Drug Use Investigation for ADOAIR (Fluticasone/Salmeterol) NCT01395849	GlaxoSmithKline	—
Completed	Safety and Efficacy Study of Depelestat in Acute Respiratory Distress Syndrome (ARDS) Patients NCT00455767	Debiopharm International SA	Phase 2